Literature DB >> 4044217

Treatment of bleeding hemorrhoids by injection sclerotherapy and rubber band ligation.

M Y Rabau, L Bat.   

Abstract

Between March 1981 and September 1982, 178 patients with first- to third-degree bleeding hemorrhoids were treated by injection sclerotherapy and rubber band ligation, as outpatients. Of the treated patients 85 to 90% were asymptomatic during 1 year of follow-up. Complications, ranging from mild to moderate, occurred in only 5.6% of the patients. We conclude that injection sclerotherapy and rubber band ligation, when properly used, are efficient, inexpensive and safe methods for the treatment of bleeding hemorrhoids.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4044217

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  3 in total

1.  Sclerobanding Is a Novel Technique for the Treatment of Second- and Third-Degree Hemorrhoidal Disease. Reply to Jongen et al. Comment on "Pata et al. Sclerobanding (Combined Rubber Band Ligation with 3% Polidocanol Foam Sclerotherapy) for the Treatment of Second- and Third-Degree Hemorrhoidal Disease: Feasibility and Short-Term Outcomes. J. Clin. Med. 2022, 11, 218".

Authors:  Francesco Pata; Luigi Maria Bracchitta; Giancarlo D'Ambrosio; Salvatore Bracchitta
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

2.  Comment on Pata et al. Sclerobanding (Combined Rubber Band Ligation with 3% Polidocanol Foam Sclerotherapy) for the Treatment of Second- and Third-Degree Hemorrhoidal Disease: Feasibility and Short-Term Outcomes. J. Clin. Med. 2022, 11, 218.

Authors:  Johannes Jongen; Jessica Schneider; Volker Kahlke; Tilman Laubert
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

3.  Sclerobanding (Combined Rubber Band Ligation with 3% Polidocanol Foam Sclerotherapy) for the Treatment of Second- and Third-Degree Hemorrhoidal Disease: Feasibility and Short-Term Outcomes.

Authors:  Francesco Pata; Luigi Maria Bracchitta; Giancarlo D'Ambrosio; Salvatore Bracchitta
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.